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Abstract
Hepatoprotection is an important issue in Taiwan. Currently, a toxic chemical substance, carbon tetrachloride (CCl4), is used to
induce liver damage in animal models that is employed to evaluate the hepatoprotective effects of health food in Taiwan. To provide a
more flexible and accessible research model, this study was aimed to establish a standardized animal model of chronic hepatotoxicity
using the common drug, acetaminophen; an overdose of this drug causes acute liver damage in experimental animals. Four animal
strains from 2 species (ICR mice and BALB/c mice via intraperitoneal injection; Sprague-Dawley rats and Wistar rats via oral administration) were used as subjects in this study. Acetaminophen at various dosages was administered for 8 weeks, and then biochemical
and histopathological examinations were performed. The results showed that acetaminophen significantly induced liver damage in mice
by intraperitoneal injection, but not in rats by oral administration. The individual variation in BALB/c mice was less than that in ICR
mice. Acetaminophen increased serum aspartate transaminase (AST), alanine transaminase (ALT), and glutathione (GSH) content. The
glutathione reductase (GRd), superoxide dismutase (SOD), and catalase (CAT) activity were inhibited after acetaminophen injection
in BALB/c mice in a dose-dependent manner. The highest dose of acetaminophen was lethal to mice. In terms of histopathological
examination, acetaminophen caused hepatic necrosis and inflammation, consistent with the pathological progress found in humans. On
the other hand, the liver protective effect of N-acetylcysteine (NAC) in BALB/c mice was analyzed. The data revealed that pretreatment
with NAC significantly protected liver from damage induced by 400 mg acetaminophen/kg bw in BALB/c mice, and there was no
significant difference between the 600 and 1200 mg NAC/kg bw groups. In conclusion, acetaminophen at the dose of 400 mg/kg bw
could induce reproducible liver damage in BALB/c mice, and NAC (600 mg/kg bw) is a suitable protective drug in this animal model
for the evaluation of hepatoprotective effects of health food.
Key words: acetaminophen, ICR mice, BALB/c mice, SD rats, Wistar rats, health foods, liver damage, NAC

Introduction
Liver disease is one of the leading causes of death in
Taiwan. Many animal models have been introduced to study
hepatic fibrosis induced by hepatotoxic substances found in
diet, drugs, or alcohol. Moreover, these animal models have
been used to investigate possible mechanisms of hepatic
damage, such as bile duct ligation or immunologic activation. Carbon tetrachloride (CCl4) has been used widely in
animal models to induce chronic liver injury(1,2). However,
CCl4 is not a common cause of liver injury in the clinical
setting, and furthermore, CCl4 is cumbersome to use since
it is a toxic chemical substance. Hence, it is necessary to
* Author for Correspondence. Tel: +886-2-33664129;
Fax: +886-2-23620849; E-mail address: lysheen@ntu.edu.tw

establish an easily accessible and standardized animal model
of chronic liver injury.
Acetaminophen is a widely used, safe, and effective
analgesic and antipyretic. However, overdose of acetaminophen leads to liver failure and death in experimental animals
and humans(3), and is a leading cause of drug-induced acute
liver failure in the United States(4). Acetaminophen is metabolized to a highly reactive and toxic metabolite N-acetyl-pbenzoquinone imine (NAPQI) by cytochrome P450 2E1
(CYP2E1)(5). Under normal conditions, NAPQI is detoxified
by glutathione (GSH). However, under conditions of overdose, GSH is depleted and excess NAPQI binds to cellular
proteins, thereby increasing oxidative stress and inducing
liver necrosis(6-8). Since oxidative stress is the main hepatotoxic factor in acetaminophen overdose(9), N-acetylcysteine
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(NAC), an antioxidant providing cysteine for glutathione
synthesis(10,11), is used in the clinical setting for the treatment
of acetaminophen overdose(12,13).
In experimental animal studies, acetaminophen is a
common chemical used to induce liver injury. However, the
results of these studies are controversial, owing to the fact
that acetaminophen toxication and detoxification effects can
vary with the species of experimental animals, the dose of
acetaminophen, the route of drug administration, etc.(14,15)
In short, acetaminophen has not been standardized as an
experimental animal model of liver injury(16).
Therefore, the aims of this study were to establish
a standardized animal model of acetaminophen-induced
chronic liver injury, by comparing different animal species
and strains with different doses of acetaminophen, and to
further verify the suitable dose of the protective drug, NAC.

Materials and methods
I. Materials and Chemicals
Acetaminophen, reduced glutathione (GSH), KH2PO4,
K 2HPO4, KCl, NaCl, and NAC were obtained from SigmaAldrich Chemicals Company (St. Louis, MO, USA). Glutathione (GSH), glutathione reductase (GRd), superoxide
dismutase (SOD), and catalase (CAT) assay kits were
purchased from Cayman Chemical Company (Ann Arbor,
MI, USA). SPOTCHEMTM II GPT Reagent Strips and
SPOTCHEMTM II GOT Reagent Strips were from Arkray
Inc. (Kyoto, Japan).
II. Animals
Male BALB/c mice, ICR mice, and Wistar rats were
purchased from National Taiwan University Hospital
(Taipei, Taiwan); Sprague-Dawley (SD) rats were obtained
from BioLASCO Taiwan Co. (Taipei, Taiwan). All animals
were housed in a controlled room (22 ± 3°C, 50 - 70% of relative humidity, and a 12-h light: dark cycle); standard rodent
chow diet and water were provided ad libitum.
III. Experimental Design of Chronic Acetaminophen
Hepatotoxicology
BALB/c and ICR mice weighing about 18 g (7 weeks
old) were randomly divided into 4 groups. Group 1 served
as the normal control group, and groups 2 - 4 were the test
groups injected with varying amounts of acetaminophen.
Each group of animals were injected intraperitoneally twice
a week for 8 weeks with isotonic 0.9% NaCl and acetaminophen, in the following amounts: 200 , 400 and 600 mg/kg bw
for group 2, 3 and 4, respectively.
Sprague-Dawley and Wistar rats weighing about 200 g
(7 weeks old) were randomly divided into 4 groups. Rats
were orally given pure water, and 1.5, 2.5, or 3.5 g acetaminophen/kg bw twice a week for 8 weeks in group 1, 2, 3 and

4, respectively.
At the end of the first, third, and sixth weeks of the
experiment, 2 rodents from each group were sacrificed for
the observation of liver injury progress. At the end of the
eight week, all animals were sacrificed for biochemical and
histological analysis.
IV. Experimental Design of the Protective Effect of NAC on
Acetaminophen-Induced Chronic Hepatotoxity
Male BALB/c mice weighing about 20 g (8 weeks
old) were divided into 4 groups. Groups 1 and 2 served as
normal control and negative control groups, and were given
0.5% carboxymethyl cellulose (CMC) orally once daily
for 9 weeks. The NAC groups 3 and 4 were treated orally
with 600 and 1200 mg NAC/kg bw (in 0.5% CMC), respectively, once daily for 9 weeks. After the second week of the
experimental period, groups 2, 3, and 4 were intraperitoneally injected with acetaminophen (400 mg/kg bw) twice a
week for 8 weeks, 1 hr before NAC treatment, while group 1
received saline injection.
V. Analysis of Serum Parameters
Blood from retro-ocular sinuses of mice or celiac
arteries of rats were collected in heparin tubes. The blood
samples were centrifuged at 12,000 rpm at 4°C for 5 min
to separate the serum. Liver injury was determined by
measuring aspartate transferase (AST) and alanine transaminase (ALT) activities in serum using SPOTCHEMTM II
GOT Reagent Strips and SPOTCHEMTM II GPT Reagent
Strips, respectively, on an automated biochemical analyzer
(SPOTCHEMTM EZ SP-4430, ARKRAY Inc, Kyoto, Japan).
VI. Estimation of Hepatic GSH and Anti-Oxidative Enzymes
As each rodent was sacrificed, the liver was immediately removed, washed with ice-cold saline, weighed, and
stored at −80°C. A portion of each liver was homogenized
(1 : 10, w/v) in phosphate buffer (8 mM KH2PO4, 12 mM
K 2HPO4, 1.5% KCl, pH 7.4), and the homogenate was
centrifuged at 10,000 g for 30 min at 4°C. The resultant
supernatant was used for analysis. Hepatic GSH and GRd
levels and activities of CAT and SOD were determined by
ELISA using commercial kits (Cayman Chemical, USA).
GSH kit measures the content of 5-thio-2-nitrobenzonic
acid produced from GSH and 5,5’-dithio-bis-2-(nitrobenzoic
acid) for the quantification of GSH. GRd assay kit estimates
GRd activity by measuring the rate of NADPH oxidation.
CAT assay kit utilizes the peroxidatic function of CAT for
confirmation CAT activity. The assay kit of SOD uses tetrazolium salt for detection of superoxide radicals generated by
xanthine oxidase and hypoxanthine.
VII. Histopathological Examination
A portion of each liver tissue was fixed in 10% buffered
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Table 1. Effect of acetaminophen on serum contents of AST, ALT, and GSH, and hepatic enzyme activities of GRd, CAT, and SOD for
different species of rodents
serum
Animal

Group

AST

liver
ALT

GSH

(IU/L)
ICR mice

Control

SD rats

170 ± 72b

b

b

103 ± 8a

Acetaminophen 200

87 ± 47

Acetaminophen 400

11798 ± 7600a

7757 ± 3111a

Acetaminophen 600

a

a

BALB/c mice Control

Wistar rats

51 ± 26b

164 ± 97

26540 ± 3167
38 ± 11

c

68 ± 17

10830 ± 1541
c

64 ± 17

Acetaminophen 200

169 ± 60bc

Acetaminophen 400

b

319 ± 159

428 ± 288

Acetaminophen 600

6375 ± 771a

3770 ± 410a

ab

150 ± 76c

90 ± 10

44 ± 3

Acetaminophen 1500

79 ± 15b

59 ± 14b

Acetaminophen 2500

61 ± 6

Acetaminophen 3500

134 ± 72a

Control
Acetaminophen 1500

58 ± 7

b

b

Control

b

GRd

(nmol/mg protein)

b

155 ± 136a

94 ± 20

53 ± 6

101 ± 16

76 ± 17

CAT

56 ± 8a
ab

52 ± 17

79 ± 4bc

SOD
(U1/mg protein)

(nmol/mg protein/min)
ab

11.1 ± 0.3

2.4 ± 0.8a

11.1 ± 0.7

1.2 ± 0.9b

10.2 ± 0.6

c

0.9 ± 1.0b

11.1 ± 0.3

a

47 ± 6

a

2.8 ± 0.8

11.2 ± 2.8a

66 ± 5b

21 ± 5b

1.4 ± 0.7b

8.6 ± 0.4b

b

b

b

1.6 ± 0.4

8.2 ± 0.2b

1.2 ± 0.4b

7.5 ± 1.6b

8.6 ± 1.7

b

18.0 ± 0.6

1.8 ± 0.1b

37.9 ± 3.4c

24.8 ± 3.4c

17.0 ± 0.3c

1.9 ± 0.1a

b

b

34.7 ± 3.6

b

18.3 ± 0.9

1.6 ± 0.2c

38.4 ± 2.4a

47.9 ± 2.4a

19.3 ± 0.3a

1.2 ± 0.1d

a

a

80 ± 7

c

83 ± 6

a

69 ± 4

40 ± 4bc

3.1 ± 0.3a

30 ± 7

16 ± 4

38 ± 4b

14 ± 4b

102.9 ± 1.7
36.9 ± 3.6

d

d

24.4 ± 3.4

28.4 ± 0.6

2.1 ± 0.08b

50.8 ± 3.6a

26.1 ± 3.6a

27.1 ± 0.8c

2.1 ± 0.07b

b

b

103.5 ± 3.4

Acetaminophen 2500

109 ± 33

100 ± 32

40.5 ± 6.2

Acetaminophen 3500

109 ± 57

105 ± 75

32.4 ± 4.8c

12.0 ± 6.2

5.9 ± 4.8c

ab

bc

27.4 ± 1.3

2.1 ± 0.15b

29.5 ± 1.1a

2.4 ± 0.12a

Data are expressed as mean ± SD (n = 6 - 8).
Indicate groups with statistical difference (p < 0.05) by one-way ANOVA coupled with the Duncan’s multiple range test. AST, aspartate
aminotransferase; ALT, alanine aminotransferase; GSH, glutathione; GRd, glutathione reductase; SOD, superoxide dismutase; CAT, catalase
1
One unit of SOD is defined as the amount of enzyme needed to exhibit 50% dismutation of the superoxide radical.
abc

neutral formalin solution, embedded in paraffin, sectioned
into 3 μm thick slices, and stained with hematoxylin and
eosin (HE). The liver tissue injury was examined by a histopathological expert under optical microscope. Histology
activity index, graded on severity scales from none (0), mild
(1), moderate (2) to severe (3), is used to quantify the degree
of liver inflammation(17).
VIII. Statistical Analysis
All data were expressed as a mean ± standard deviation (SD) (n = 6 - 8). The data were analyzed using one-way
analysis of variance (ANOVA), followed by Duncan’s
multiple range test for individual comparisons, using SAS
9.1 software (SAS Institute Inc., USA). Data were considered
statistically significant when the P value was less than 0.05.

Results
I. Species Differences of Chronic Acetaminophen-Induced
Chronic Hepatotoxity
As shown in Table 1, serum levels of ASL and ALT
increased significantly in ICR and BALB/c mice groups
injected with 200 or 400 mg/kg bw acetaminophen for

Table 2. Serum contents of AST and ALT in BALB/c mice after 400
mg acetaminophen/kg bw treatment
week
0

1

3

6

8

AST (IU/L) 86 ± 18b 221 ± 117a 263 ± 120a 298 ± 137a 428 ± 288a
ALT (IU/L) 57 ± 14b 318 ± 134a 366 ± 308a 423 ± 111a 319 ± 159a
Data are expressed as mean ± SD (n = 6 - 8).
ab
Indicate groups with statistical difference (p < 0.01) by one-way
ANOVA coupled with the Duncan’s multiple range test.
AST, aspartate aminotransferase; ALT, alanine aminotransferase

8 weeks as compared with the control group (p < 0.05).
Serum AST and ALT levels in BALB/C mice were analyzed
at different time points in the experiment (Table 2). After
1 week of acetaminophen treatment, AST and ALT increased
significantly (p < 0.01), but stayed unchanged at week 3, 6,
and 8. In rats, acetaminophen administration significantly
elevated the serum levels of ASL and ALT in Wistar rats (p <
0.05) at the dose of 3500 mg/kg bw, but no significant change
was observed in SD rats.
The hepatic GSH content of BALB/c mice, Wistar rats
and SD rats, treated with different doses of acetaminophen,
depleted significantly to different degrees, as compared to
control groups (p < 0.05).
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In terms of the activities of anti-oxidative enzymes in
liver, the higher doses (400 and 600 mg acetaminophen/kg
bw) of acetaminophen significantly suppressed the GRd and
CAT activities in ICR mice, but no effect was seen in SOD
activity. In BALB/c mice, various doses of acetaminophen
resulted in a dose-dependent and significant decrease of all
enzyme activities compared with control groups (p < 0.05).
On the other hand, acetaminophen boosted GRd and CAT
activities significantly (p < 0.05) in Wistar rats. The GRd
activity was diminished after 3,500 mg acetaminophen/kg
bw treatment in SD rats, but SOD and CAT activities
increased significantly (p < 0.05).
To confirm the hepatotoxicity of acetaminophen, histopathological examinations on each liver were performed
and demonstrated the progress of liver damage in BALB/c
mice induced by 400 and 600 mg/kg bw acetaminophen.
The histological studies revealed that acetaminophen
induced necrosis and inflammation in the liver tissue,
especially at the end of the eight week. Similar results were
observed in ICR mice. Histological examination of liver
from Wistar and SD rats revealed increased tissue collagen
in the periportal area, an increase in the number of bile
ducts, and the vacuolation of hepatocytes around the central
vein (data not shown). However, the severity of liver damage
was generally low.
II. Effect of NAC on Acetaminophen-Induced Chronic Liver
Damage
The protective effects of NAC on AST and ALT in
serum and GSH level in liver from male BALB/c mice
treated with acetaminophen are shown in Table 3. Oral
administration of 600 and 1200 mg NAC/kg bw in BALB/c
mice treated with 400 mg acetaminophen/kg bw, significantly lowered serum AST and ALT, while GSH levels
increased (p < 0.05). No significant difference on AST,
ALT, and GSH were found between the 600 and 1200 mg
NAC/kg bw groups.
The histological examinations showed that acetaminophen treatment induced inflammation in the liver tissue, and
blood congestion was observed (Figure 1B). Pretreatment
with 600 or 1200 mg NAC/kg bw markedly mitigated the
inflammation in hepatic lobules (Figure 1C & 1D). Histological activity indices of control, acetaminophen, NAC
(600 and 1200 mg/kg) groups were 0 ± 0, 0.6 ± 0.2, 0 ± 0,
and 0 ± 0 on hepatic lobules inflammation, respectively,
which indicated that acetaminophen significantly induced
inflammation (p < 0.05) while NAC significantly eased the
acetaminophen-induced inflammation.

Discussion
The animal model of hepatotoxicity induced by CCl4 is
an official methodology in Taiwan for the evaluation of hepatoprotective effects of health foods. However, this model has
little relevance to humans since hepatotoxicity induced by

Table 3. Effect of pretreatment with NAC on serum AST, ALT, and
hepatic GSH content after acetaminophen treatment in BALB/c
mice
Group
control
Acetaminophen

AST
(IU/L)

ALT
(IU/L)

GSH
(nmol/
mg protein)

72 ± 17b

37 ± 14b

112 ± 19a

206 ± 107a

48 ± 19b

234 ± 118a
b

Acetaminophen + NAC 600

143 ± 117

Acetaminophen + NAC 1200

101 ± 20b

b

104 ± 37a

65 ± 38b

108 ± 11a

100 ± 58

Data are expressed as mean ± SD (n = 6 - 8).
Indicate groups with statistical difference (p < 0.05) by one-way
ANOVA coupled with the Duncan’s multiple range test.
AST, aspartate aminotransferase; ALT, alanine aminotransferase;
GSH, glutathione
abc

CCl4, a toxic chemical substance, is a rare occurrence in
humans. Therefore, acetaminophen, with similar metabolic
and toxic responses in both rodents and humans(18), was
planned to be the substitute drug to induce liver toxicity in
animal models. Hence, the goal of this study was to build a
standardized model of acetaminophen-induced liver injury.
Under therapeutic doses, acetaminophen is detoxified in
the liver mainly by glucuronidation and sulfation(19,20). Part
of acetaminophen is metabolized by CYP450(21) CYP2E1,
and is converted to a toxic metabolite NAPQI(22). NAPQI
is detoxified by conjugation with glutathione (GSH)(6); thus,
GSH content is the critical factor of acetaminophen toxicity.
Under the condition of acetaminophen overdose, glucuronidation and sulfation become saturated, GSH is depleted, and
NAPQI is bound to cellular proteins, resulting in oxidative
stress and liver necrosis(23,24).
Mechanistically, acetaminophen is assumed to increase
the serum levels of AST and ALT, and the indices of liver
injury, and to decrease GSH content and GRd activity,
which is an essential enzyme for the regeneration of GSH
from glutathione disulphide (GSSG). The activities of CAT
and SOD, the antioxidant enzymes, were expected to be
decreased after acetaminophen treatment. In this study,
in the majority of the cases, acetaminophen injection at
the dose of 400 and 600 mg/kg bw significantly increased
AST and ALT, decreased GSH, and decreased the activity
of GRd, CAT and SOD in mice. There was one exception:
the SOD activity in ICR mice was not statistically different
from the control (Table 1). These findings are similar to
previous studies(25-31). Because the survival rate of BALB/c
mice at the end of the experiment in 600 mg acetaminophen/
kg bw group (19%) was significantly lower than that in
400 mg acetaminophen/kg bw group (90%), it is suggested
acetaminophen at the dose of 400 mg/kg bw is optimal for
hepatotoxicity induction studies.
Perivenular (zone 3) necrosis is a characteristic lesion
induced by intrinsic toxins, including acetaminophen. In
the case of acetaminophen overdose, confluent coagulative necrosis occurs in perivenular and mid-zones(32). The
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Figure 1. Hepatoprotective effect of NAC on acetaminophen-induced liver damage in BALB/c mice (H&E stain 100 X).
(A) Normal control group (B) Acetaminophen group (400 mg acetaminophen/kg bw, i.p.) (C) Acetaminophen + NAC (600 mg/kg bw, p.o.)
(D) Acetaminophen + NAC (1200 mg/kg bw, p.o.)

progress of liver damage in the pathological examination of
BALB/c mice induced by acetaminophen is consistent with
that of human. Histological activity index scoring, a system
for quantifying the degree of liver inflammation, supported
the histological results (data not shown).
By reporting the effects of acetaminophen on the
biochemical and histopathological parameters of liver
damage, the present study demonstrated that acetaminophen
induced liver injury to different species and animal strains to
different extents. In both Wistar and SD rats, acetaminophen
treatment did not induce severe injury even at the extremely
toxic dosage (3500 mg/kg bw). The results of biochemical
and histological examination results similar in BALB/c and
ICR mice, but the individual variation was observed more
often in ICR mice than in BALB/c mice. The different
responses to acetaminophen by species and strains may be
due to their different elimination pathways of acetaminophen. Previous studies have showed that mice and hamsters
are sensitive, while rats, rabbits, and guinea pigs are less
sensitive to acetaminophen toxicity. Strain specificities also

exist(7,33). In sensitive species or strains, acetaminophen is
excreted mainly via toxication pathway-related metabolites,
glutathione conjugate and its metabolites, by the CYP450
enzymatic reaction(14,34,35). The ratio of toxication/detoxication-pathway metabolites of acetaminophen in liver slices
is related to the response of acetaminophen in different
species(36). In vitro studies also demonstrate interspecies
differences in sensitivity to acetaminophen (37,38). These
findings provide adequate explanation that acetaminophen
treatment led to various levels of liver injury in different
species and strains in our study.
GSH is an endogenous antioxidant and thus its presence is related to numerous diseases(39). NAC, a watersoluble and easily absorbed chemical, is a precursor of GSH
that provides cysteine, an amino acid that forms GSH(10,11).
Therefore, NAC is used to treat several critical illnesses,
such as severe liver damage, renal failure, and acetaminophen overdose(40,41). Hence, we used NAC as a protective
drug in this animal model. The dosage of NAC used (600
and 1200 mg/kg bw) was converted from the oral dose (140
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mg/kg, followed by 70 mg/kg every 4 h for 17 doses) that
is typically used in the clinical setting(42). The biochemical
and histological examinations showed that NAC treatment
via gavage significantly mitigated liver injury induced by
acetaminophen in BALB/c mice. In this chronic model, there
was no difference observed between these 2 doses.
In conclusion, the animal model of acetaminopheninduced chronic hepatotoxicity is standardized in this study.
Acetaminophen administration (i.p.) at the dose of 400 mg/
kg bw twice a week for 8 consecutive weeks on BALB/c
mice is the optimal condition to induce liver injury. NAC at
600 mg/kg bw is an effective protective drug in this animal
model. This model of acetaminophen-induced hepatotoxicity may be useful to evaluate the hepatoprotective effect
of health foods.
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